Hypoxia Imaging With 18F FAZA. Prognostic Impact in Cervical Cancer - Full Text View

Hypoxia Imaging With 18F FAZA. Prognostic Impact in Cervical Cancer

This study is currently recruiting participants.
Verified by Medical University of Vienna, October 2006

Sponsored by:	Medical University of Vienna
Information provided by:	Medical University of Vienna
ClinicalTrials.gov Identifier:	NCT00388687

Purpose

The aim of this study is to visualize the tumor hypoxic tissue, the potential quantitative changes and the biological behavior of cervical carcinoma (primary and / or lymph nodes) before, during and after radiochemotherapy with the novel hypoxia PET tracer 18FAZA.

Condition	Intervention	Phase
Uterine Cervical Neoplasms	Drug: 18F Fluoroazomycin Arabinoside (FAZA)	Phase II

MedlinePlus related topics:

Cancer Cervical Cancer

U.S. FDA Resources

Study Type:	Observational
Study Design:	Longitudinal, Defined Population, Prospective Study

Official Title:	Hypoxia Imaging With the Novel Radiopharmaceutical 18F Fluoroazomycin Arabinoside (FAZA)- Prognostic Impact in Cervical Cancer

Further study details as provided by Medical University of Vienna:

Estimated Enrollment:	25
Study Start Date:	July 2006
Estimated Study Completion Date:	July 2007

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

First diagnosis of histologically proven cervical cancer FIGO stage IB2 to IVA.
Treatment intention for the purpose of achieving cure
Age < 80 years
No previous standard or radical hysterectomy

Exclusion Criteria:

Pregnancy, breast-feeding women, patients that are not able to lie motionless for one hour.Palliative treatment, recurrent disease, neoadjuvant chemotherapy, other pre-existing malignancies, age > 80 years,

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00388687

Contacts


Contact: Matthias Schuetz, M.D.	00431404005550	matthias.schuetz@meduniwien.ac.at

Contact: Barbara Bachtiary, Prof. M.D	00431404007676	barbara.bachtiary@meduniwien.ac.at

Locations


Austria
	Medical University of Vienna	Recruiting
	Vienna, Austria, 1090
	Contact: Barbara Bachtiary, Prof. M.D. 00431404007676 barbara.bachtiary@meduniwien.ac.at
	Principal Investigator: Georgios Karanikas, Prof. M.D.
	Medical Universitiy of Vienna	Recruiting
	Vienna, Austria, 1090
	Contact: Barbara Bachtiary, Prof. M.D. 00431404007676 barbara.bachtiary@meduniwien.ac.at

Sponsors and Collaborators

Medical University of Vienna

Investigators


Study Director:	Georgios Karanikas, Prof. M.D.	Medical Universitiy of Vienna

More Information

Study ID Numbers:	EK Nr: 241/2006
First Received:	October 16, 2006
Last Updated:	October 16, 2006
ClinicalTrials.gov Identifier:	NCT00388687
Health Authority:	Austria: Federal Ministry for Health and Women

Keywords provided by Medical University of Vienna:

Hypoxia

FAZA

PET

Radiochemotherapy

Study placed in the following topic categories:

Genital Diseases, Female

Uterine Cervical Neoplasms

Signs and Symptoms

Uterine Cervical Diseases

Genital Neoplasms, Female

Signs and Symptoms, Respiratory

Uterine Diseases

Uterine Neoplasms

Urogenital Neoplasms

Anoxia

Additional relevant MeSH terms:

Neoplasms

Neoplasms by Site

ClinicalTrials.gov processed this record on September 19, 2008